Persistence of the immune response after MenACWY-CRM vaccination and response to a booster dose, in adolescents, children and infants

Five-year Antibody Persistence and Booster Response to a Single Dose of Meningococcal A, C, W and Y Tetanus Toxoid Conjugate Vaccine in Adolescents and Young Adults

(2015) Roger Baxter et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Comparative Assessment of a Single Dose and a 2-Dose Vaccination Series of a Quadrivalent Meningococcal CRM-Conjugate Vaccine (MenACWY-CRM) in Children 2–10 Years of Age

(2015) William Johnston et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same Vaccines

(2015) Timo Vesikari et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

A native outer membrane vesicle vaccine confers protection against meningococcal colonization in human CEACAM1 transgenic mice

(2015) Rolando Pajon et al.   VACCINE

Antibody persistence 5 years after vaccination at 2 to 10 years of age with Quadrivalent MenACWY-CRM conjugate vaccine, and responses to a booster vaccination

(2015) Stan L. Block et al.   VACCINE

Serum bactericidal antibody assays – The role of complement in infection and immunity

(2015) E.D.G. McIntosh et al.   VACCINE

Persistent low carriage of serogroup A Neisseria meningitidistwo years after mass vaccination with the meningococcal conjugate vaccine, MenAfriVac

(2014) Paul A Kristiansen et al.   BMC INFECTIOUS DISEASES

Immunogenicity and safety of a quadrivalent meningococcal polysaccharide CRM conjugate vaccine in infants and toddlers

(2014) Miguel Tregnaghi et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Antibody Persistence and Booster Response of a Quadrivalent Meningococcal Conjugate Vaccine in Adolescents

(2014) Roger Baxter et al.   JOURNAL OF PEDIATRICS

Antibody Persistence After Primary and Booster Doses of a Quadrivalent Meningococcal Conjugate Vaccine in Adolescents

(2014) Roger Baxter et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study

(2013) Charissa Borja-Tabora et al.   BMC INFECTIOUS DISEASES

Effect of a serogroup A meningococcal conjugate vaccine (PsA–TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study

(2013) DM Daugla et al.   LANCET

One or Two Doses of Quadrivalent Meningococcal Serogroups A, C, W-135 and Y Tetanus Toxoid Conjugate Vaccine Is Immunogenic in 9- to 12-Month-Old Children

(2013) Nicola P. Klein et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Effectiveness of meningococcal serogroup C vaccine programmes

(2013) Ray Borrow et al.   VACCINE

Persistence of antibodies for 42 months following vaccination of adolescents with a meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine (MenACWY-TT)

(2012) Lars Østergaard et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Antibody Persistence and Response to a Booster Dose of a Quadrivalent Conjugate Vaccine for Meningococcal Disease in Adolescents

(2012) Robert M. Jacobson et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers

(2012) Timo Vesikari et al.   Human Vaccines & Immunotherapeutics

Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents

(2011) Christopher J. Gill et al.   Human vaccines & immunotherapeutics

Safety and Immunogenicity of a Novel Quadrivalent Meningococcal CRM-conjugate Vaccine Given Concomitantly With Routine Vaccinations in Infants

(2011) Nicola P. Klein et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Meningococcal carriage by age: a systematic review and meta-analysis

(2010) Hannah Christensen et al.   LANCET INFECTIOUS DISEASES

Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2–10 years of age

(2010) Scott A. Halperin et al.   VACCINE

Ex Vivo Model of Meningococcal Bacteremia Using Human Blood for Measuring Vaccine-Induced Serum Passive Protective Activity

(2009) J. S. Plested et al.   Clinical and Vaccine Immunology

Investigation of Different Group A Immunoassays following One Dose of Meningococcal Group A Conjugate Vaccine or A/C Polysaccharide Vaccine in Adults

(2009) H. Findlow et al.   Clinical and Vaccine Immunology

Quadrivalent Meningococcal Vaccination of Adults: Phase III Comparison of an Investigational Conjugate Vaccine, MenACWY-CRM, with the Licensed Vaccine, Menactra

(2009) K. S. Reisinger et al.   Clinical and Vaccine Immunology

Global epidemiology of meningococcal disease

(2009) Lee H. Harrison et al.   VACCINE

Vaccine-Induced Opsonophagocytic Immunity to Neisseria meningitidis Group B

(2008) J. S. Plested et al.   Clinical and Vaccine Immunology

Immunogenicity of a Tetravalent Meningococcal Glycoconjugate Vaccine in Infants

(2008) Matthew D. Snape et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION